VEGFA and neoplasm: Increasing the uptake of co-administered chemotherapies by overcoming the high interstitial fluid pressures in the tumor microenvironment has previously been accomplished through inhibition of the PDGF receptor with imatinib [60], [61], remodeling of the extracellular matrix using collagenase and hyaluronidase [8], [62], vascular normalization using anti-VEGF antibodies [7] and targeted vasopermeation using PEP [63] (for review, see Cairns et al., 2006 [64]).